Abstract:Patients with gain-of-function (GoF) mutations of glutamate dehydrogenase (GDH) have protein-sensitive hypoglycemia, hyperammonemia, epilepsy, and intellectual disability (HI/HA syndrome). Studies of mouse models with a beta-cell specific expression of H454Y hGDH suggest that the mechanisms of HI are caused by increased glutaminolysis induced by GDH GoF in islets. However, the mechanism of hyperammonemia is still unknown. In order to study the systemic effects of GDH GoF, H454Y GDH knockin mice (H454Y-GDH-KI) were created. Enzyme kinetic of GDH in the brain, kidney and liver confirmed that H454Y was successfully expressed with impaired GTP inhibition. H454Y-GDH-KI mice have a ~2.5-fold elevation of plasma ammonia and fasting hypoglycemia, similar to HI/HA patients. Tissues (brain, liver and kidney) and plasma amino acids profiles were determined by LC-MS. Compared to wildtype, the amino acids profile in the kidney was unaltered in KI mice. In contrast, KI liver had 60% lower glutamine, unchanged glutamate and aspartate, increased branch chain amino acids, etc. The glutamine of KI brain was 40% lower than the wildtype, glutamate and GABA was unchanged. Interestingly, plasma glutamine in KI mice was 30% higher compared to controls. A similar phenomenon has also been observed in HI/HA patients. We hypothesize that hyperammonemia is mainly caused by the increased glutaminolysis in KI liver. Higher plasma glutamine can be explained by the increased activity of tissue glutamine synthetase (GS). GS and glutamine serve as an ammonia sink, which is the main mechanism for the removal of increased ammonia in KI mice. We therefore applied the GS inhibitor, methionine sulfoximine (MSO) to KI mice. MSO significantly increased ammonia levels in KI mice after a single dose of injection. These studies in H454Y-GDH-KI mice suggest that GDH GoF in the liver is the main cause of hyperammonemia. GS plays an important role in ammonia removal. Disclosure C.Su: None. D.Han: Employee; Nanjing AscendRare Pharmaceutical Technology. S.Meng: Employee; Nanjing AscendRare Pharmaceutical Technology. Q.Zhu: Employee; Nanjing AscendRare Pharmaceutical Technology. X.Zhou: Employee; Nanjing AscendRare Pharmaceutical Technology. H.Jiang: None. J.Li: None. C.Gong: None. C.Li: Employee; Hua Medicine, Nanjing AscendRare Pharmaceutical Technology. Funding Beijing Natural Science Foundation (L212037)

Systemic Alteration of Amino Acids Metabolism in Glutamate Dehydrogenase Gain-of-Function Mutation Knockin Mice

[Clinical and Genetic Analyses of a Family with Atypical Nonketotic Hyperglycinemia Caused by Compound Heterozygous Mutations in the GLDC Gene].

Glutamate Dehydrogenase 1: A Novel Metabolic Target in Inhibiting Acute Myeloid Leukaemia Progression.

Glutaminase C Overexpression in the Brain Induces Learning Deficits, Synaptic Dysfunctions, and Neuroinflammation in Mice.

Regulation of glycine metabolism by the glycine cleavage system and conjugation pathway in mouse models of non‐ketotic hyperglycinemia

The First Pediatric Case of Glucagon Receptor Defect Due to Biallelic Mutations in GCGR is Identified by Newborn Screening of Elevated Arginine

Impaired novelty acquisition and synaptic plasticity in congenital hyperammonemia caused by hepatic glutamine synthetase deficiency

Serial Deletion Reveals Structural Basis and Stability for the Core Enzyme Activity of Human Glutaminase 1 Isoforms: Relevance to Excitotoxic Neurodegeneration.

Glutamate Dehydrogenase (GDH) Regulates Bioenergetics and Redox Homeostasis in Human Glioma

Targeting hepatic glutaminase activity to ameliorate hyperglycemia

Glutaminase 2 knockdown reduces hyperammonemia and associated lethality of urea cycle disorder mouse model

A Liver-Specific Defect of Acyl-CoA Degradation Produces Hyperammonemia, Hypoglycemia and a Distinct Hepatic Acyl-CoA Pattern

Dietary protein load affects the energy and nitrogen balance requiring liver glutamate dehydrogenase to maintain physical activity

GDH1-catalytic glutaminolysis feedback activate EGFR/PI3K/AKT pathway and reprogram glioblastoma metabolism

The Structure and Allosteric Regulation of Glutamate Dehydrogenase

Homozygosity for disease-causing variants in AMT and GLDC in a patient with severe nonketotic hyperglycinemia

The Metabolite Saccharopine Impairs Neuronal Development by Inhibiting the Neurotrophic Function of Glucose-6-Phosphate Isomerase

L2hgdh Deficiency Accumulates L-2-hydroxyglutarate with Progressive Leukoencephalopathy and Neurodegeneration

Deficient brain GABA metabolism leads to widespread impairments of astrocyte and oligodendrocyte function

Deep postnatal phenotyping of a new mouse model of nonketotic hyperglycinemia

The pleiotropic effects of the glutamate dehydrogenase (GDH) pathway in Saccharomyces cerevisiae